Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
2.19 (USD) • At close December 27, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.437 | 3.238 | 2.217 | 0.6 | 0.047 | 0.044 | 0.024 |
| Gross Profit
| -0.437 | -3.238 | -2.217 | -0.6 | -0.047 | -0.044 | -0.024 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 59.35 | 64.437 | 96.829 | 48.209 | 21.753 | 6.95 | 3.453 |
| General & Administrative Expenses
| 27.11 | 28.391 | 30.043 | 21.361 | 7.579 | 1.954 | 0.666 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 27.11 | 28.391 | 30.043 | 21.361 | 7.579 | 1.954 | 0.666 |
| Other Expenses
| 0 | -0.354 | -2.188 | -1.724 | 0.006 | -0.016 | -0.006 |
| Operating Expenses
| 86.46 | 92.828 | 126.872 | 69.57 | 29.332 | 8.904 | 4.119 |
| Operating Income
| -86.46 | -92.828 | -126.872 | -69.57 | -8.904 | -8.904 | -4.119 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.018 | 1.659 | 1.276 | 2.316 | -5.926 | -0.027 | -0.483 |
| Income Before Tax
| -82.442 | -88.919 | -125.596 | -67.254 | -35.258 | -8.931 | -4.602 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -4.399 | -2.393 | -1.775 | 5.885 | -0.027 | 0.059 |
| Net Income
| -82.442 | -84.52 | -123.203 | -65.479 | -41.143 | -8.931 | -4.602 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.88 | -2.33 | -3.4 | -1.99 | -1.15 | -0.64 | -0.64 |
| EPS Diluted
| -1.88 | -2.33 | -3.4 | -1.99 | -1.15 | -0.64 | -0.64 |
| EBITDA
| -86.023 | -92.32 | -126.667 | -66.654 | -29.285 | -8.887 | -4.095 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |